Lipids as Pharmacological Targets in Age-Related Lens Disease
Summary
- Cataract and presbyopia are the world’s leading causes of age-related vision impairment, affecting millions and posing significant challenges for patient care.
- A research team from Bascom Palmer Eye Institute is exploring non-surgical therapies that focus on the lens lipidome as a promising target for pharmacological treatment.
- The study research showed that, as people get older, the lens in the eye has more “stiff” fats (sphingolipids) and fewer “flexible” fats (glycerophospholipids).
Cataract and presbyopia are the world’s leading causes of age-related vision impairment, affecting millions and posing significant challenges for patient care. While surgery remains the primary treatment for cataracts and corrective lenses for presbyopia, many people lack access to these solutions due to cost, availability or geography.
A research team from Bascom Palmer Eye Institute, part of the University of Miami Miller School of Medicine, is exploring new, non-surgical therapies that focus on the lens lipidome as a promising target for pharmacological treatment. The strategies for these studies, led by Sanjoy Bhattacharya, Ph.D., and Ta Chen Peter Chang, M.D., both Bascom Palmer professors of ophthalmology, was recently published in Trends in Pharmacological Sciences.
Researchers Ruminder Preet Kaur, a Miller School master’s degree student, and Joshua Josef, a Miller School medical student, contributed significantly to the study.
Study Methodology: Mapping the Lens Lipidome
To unravel the complex role of lipids in lens health and disease, the research team employed a comprehensive, multi-step methodology:
• Collecting samples: Scientists gathered lens tissue from people (after cataract surgery or donation) and from animals to compare healthy lenses to those affected by cataract or presbyopia.
• Getting the lipids out: They used chemicals to pull out the lipids from the lens cells. These fats are important for keeping the lens clear and flexible.
• Analyzing the lipids: Researchers used mass spectrometers and imaging tools to figure out exactly which lipids were present and where they were located in the lens. This helped them see how the mix of lipids changes with age and disease.
• Studying how lipids affect the lens: They ran tests to see how changes in lipids made the lens more stiff or cloudier. For example, they looked at how crystallins stick to the lens membrane and cause cloudiness.
• Testing treatments: The team tried different treatments in lab animals and cell cultures. Some treatments aimed to replace missing lipids, others tried to reduce harmful protein clumps or protect the lens from damage.
• Trying new delivery methods: Because the lens is hard to reach, researchers explored new ways to get medicine into the eye, like using tiny nanoparticles.
• High-tech analysis: They used computer programs and artificial intelligence to help analyze all the data and improve how treatments are tested.
Key Findings
The study research showed that, as people get older, the lens in the eye has more “stiff” fats (sphingolipids) and fewer “flexible” fats (glycerophospholipids). This makes the lens less able to focus and more likely to get cloudy. In cataracts, these changes are even stronger. The lens gets even stiffer and loses some important cholesterol, which helps keep it clear.
Crystallins can clump together and stick to the lens, making it cloudy and harder for light to pass through. The lens also loses some of its natural defenses against damage (antioxidants), so it’s easier for harmful changes to happen.
Implications for Patient Care
Pharmacological therapies targeting the lens lipidome could improve the management of cataract and presbyopia, offering non-surgical options for patients. Advances in drug delivery systems, including nanoparticles, may soon enable effective, non-invasive administration of these therapies.
Bascom Palmer researchers are building on this work by testing new medicines that might help by:
• Replacing missing fats in the lens
• Stopping protein clumps
• Protecting the lens from damage
• Making the lens more flexible
While there is no viable lipid-based pharmacological therapy, Bascom Palmer’s ongoing research continues to push the boundaries of lens biology and drug development.
Tags: Bascom Palmer Eye Institute, cataracts, Dr. Peter Chang, Dr. Sanjoy Bhattacharya, eye diseases, presbyopia, vision impairment